Cardiotoxicity of Moderate Whole-Body Hyperthermia, Doxorubicin, and Combined Treatment in Rats
In clinical practice hyperthermia should enhance the cytotoxic effects of other cancer therapy modalities on tumors while not increasing side-effects on normal tissues. Interactions between hyperthermia and cytostatic drugs (Hahn 1982; Honess and Bleehen 1985; Neumann et al. 1985) on malignant cell lines or in experimental tumor models are well known, but only a few studies have been performed with defined treatment regimens in normal tissues (Overgaard and Suit 1979), especially in critical organs. In order to elucidate various toxic effects induced by combined therapy involving moderate whole-body hyperthermia (mWBH) and cytostatic drugs (thermochemotherapy, TCT) we examined specific side-effects of doxorubicin and/or mWBH.
KeywordsToxicity Oncol Doxorubicin Cardiomyopathy Noma
Unable to display preview. Download preview PDF.
- Engelhardt R (1983) Clinical trials on thermo-chemotherapy (TCT), TCT in small cell carcinoma of the lung. Strahlentherapie 159: 371–372Google Scholar
- Hahn GM (1982) Thermal enhancement of the actions of anticancer agents. In: Hahn GM (ed) Hyperthermia and cancer. Plenum, New York, pp 55–86Google Scholar
- Overgaard J (1983) Histopathologic effects of hyperthermia. In: Storm FK (ed) Hyperthermia in cancer therapy. Hall, Boston, pp 163–164Google Scholar